The Rationale for and Clinical Pharmacology of Prasugrel 5 mg.

about

The Rationale for and Clinical Pharmacology of Prasugrel 5 mg.

Item

http://www.wikidata.org/entity/Q39010701

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

The Rationale for and Clinical Pharmacology of Prasugrel 5 mg.

@en

The Rationale for and Clinical Pharmacology of Prasugrel 5 mg.

@nl

type

Item

label

The Rationale for and Clinical Pharmacology of Prasugrel 5 mg.

@en

The Rationale for and Clinical Pharmacology of Prasugrel 5 mg.

@nl

prefLabel

The Rationale for and Clinical Pharmacology of Prasugrel 5 mg.

@en

The Rationale for and Clinical Pharmacology of Prasugrel 5 mg.

@nl

P1476

The Rationale for and Clinical Pharmacology of Prasugrel 5 mg.

@en

P2093

David Erlinge

http://www.w3.org/2001/XMLSchema#string

David S Small

http://www.w3.org/2001/XMLSchema#string

Dimitrios Alexopoulos

http://www.w3.org/2001/XMLSchema#string

Dominick J Angiolillo

http://www.w3.org/2001/XMLSchema#string

Joseph A Jakubowski

http://www.w3.org/2001/XMLSchema#string

Kenneth J Winters

http://www.w3.org/2001/XMLSchema#string

Paul A Gurbel

http://www.w3.org/2001/XMLSchema#string

P2860

Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease

Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial

Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial

Dose-dependent inhibition of human platelet aggregation by prasugrel and its interaction with aspirin in healthy subjects

Integrated analysis of pharmacokinetic data across multiple clinical pharmacology studies of prasugrel, a new thienopyridine antiplatelet agent.

Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents

PharmGKB summary: very important pharmacogene information for CYP1A2.

Prasugrel plus aspirin beyond 12 months is associated with improved outcomes after TAXUS Liberté paclitaxel-eluting coronary stent placement.

Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel.

Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy.

P2888

s40256-016-0202-3

P304

109-121

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40256-016-0202-3

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-11-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27854064

http://www.w3.org/2001/XMLSchema#string